Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metapex versus zinc oxide eugenol after pulpectomy in primary molars with symptomatic irreversible pulpitis
ACTRN12623000785606Phase 3Not yet recruiting
- Sponsor
- Sana Ashfaq
- Start
- Aug 2023
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of calcium hydroxide + iodoform and zinc oxide + eugenol in irreversible pulpitis and pulpal necrosis (2 arms), sponsored by Sana Ashfaq. Primary endpoints: Pain, Tenderness and 1 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
calcium hydroxide + iodoformzinc oxide + eugenol
03
Conditions
irreversible pulpitispulpal necrosis
Beyond the preview
Go deeper on ACTRN12623000785606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000785606.